The ErbB/HER family of protein-tyrosine kinases and cancer.

By R. Roskoski. Pharmacological Research, 2014

1,304 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Emerging functions of the EGFR in cancer (2017, background): “In some cases, mutations directly disrupt the recruitment site of the E3 ligase, Cbl, in the intracellular domain of the receptor (i.e., EGFRvIV and EGFRvV mutants), thereby affecting receptor ubiquitination and lysosomal degradation (Roskoski, 2014).”
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways (2017, background): “Null mutations of any of the ErbB genes in mice cause embryonic or perinatal lethality [43,44].”
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis (2018, background): “ERb signaling in breast cancer and other circumstances are not as well elucidated as ERa at the moment.101 However, since more studies are implying a significant position for ERb in the mammary tumorigenesis, it will not be surprising if ERb turn out to be just as crucial as ERa, if not more.80 HER2”